Cancer Drugs Fund

Cancer Drugs Fund must not be forerunner to value-based pricing - EMIG

The association representing small to medium UK pharma companies says the forthcoming Cancer Drugs Fund is welcome – but must not distort NHS priorities or be a pilot for a new pricing system for all drugs.

The Ethical Medicines Industry Group (EMIG) has made the remarks in response to the government’s consultation on the Cancer Drugs Fund, the full version of which is set for launch in April this year.

NICE limits access to cancer drugs, study confirms

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests.

The review, conducted by Bristol-Myers Squibb

£600m confirmed for three year Cancer Drugs Fund

The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by NICE under the Cancer Drugs Fund.

There had been concern the Fund would be cut under last week’s Comprehensive Spending Review, but the government has now guaranteed it will provide £200 million a year until 2014.

Mission Statement

Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,

Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches